Key statistics
On Wednesday, Castle Biosciences Inc (CSTL:NMQ) closed at 20.12, 30.23% above the 52 week low of 15.45 set on May 28, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.83 |
---|---|
High | 20.22 |
Low | 19.57 |
Bid | 18.95 |
Offer | 21.37 |
Previous close | 19.76 |
Average volume | 503.33k |
---|---|
Shares outstanding | 28.87m |
Free float | 27.11m |
P/E (TTM) | -- |
Market cap | 570.52m USD |
EPS (TTM) | -0.2016 USD |
Data delayed at least 15 minutes, as of Jul 09 2025 21:00 BST.
More ▼
- Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
- Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
- Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
- New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
- Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
- Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
- Castle Biosciences Celebrates Skin Cancer Awareness Month
- Castle Biosciences Reports First Quarter 2025 Results
- Castle Biosciences to Acquire Previse
More ▼